Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 25365973.
- Also identified by DOI 10.1093/cid/ciu865.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.
Medical subject headings
- Anilides
- Carbamates
- Hepacivirus
- Hepatitis C, Chronic
- Macrocyclic Compounds
- Ribavirin
- Ritonavir
- Sulfonamides
- Uracil